PBRER vs PSUR: Key Differences in Pharmacovigilance

Understanding the differences between PBRER and PSUR is essential for global pharmacovigilance compliance, whether your organisation manages reporting internally or relies on expert PSUR services and PV literature monitoring.

Intro

PBRER vs PSUR is one of the most frequently discussed topics in pharmacovigilance, especially among professionals working with global safety reporting. Pharmaceutical companies are required to periodically evaluate the medicinal product’s safety profile throughout its lifecycle to ensure that new safety concerns are identified, assessed, and communicated to regulatory authorities. These evaluations help protect public health by continuously monitoring whether the benefit-risk balance of a medicinal product remains favourable.

Both the Periodic Safety Update Report (PSUR) and the Periodic Benefit-Risk Evaluation Report (PBRER) are periodic safety reports used after a product reaches the market. Although the terms are often used interchangeably, they are not always identical from a regulatory perspective. This article explains the purpose, structure, regulatory requirements, reporting timelines, and practical differences between PSUR vs PBRER to help pharmacovigilance and regulatory professionals determine which format is required in different regions.

What Is a PSUR in Pharmacovigilance?

A Periodic Safety Update Report (PSUR) is an aggregate safety report prepared by a marketing authorisation holder to provide a comprehensive evaluation of a medicinal product’s safety profile during a defined reporting period. PSUR was first introduced in 1992 and harmonised in 1996. Historically, PSURs focused primarily on summarising post-marketing safety experience by collecting individual adverse event reports, aggregate data, exposure information, and other relevant safety data.

Modern PSURs, particularly within the European Union, have evolved considerably. Rather than serving as a simple compilation of adverse event reporting, they include a comprehensive and critical analysis of new safety findings, emerging safety concerns, changes to the benefit-risk profile, and proposed updates to the risk management plan or reference safety information where appropriate. This scientific evaluation supports ongoing drug safety monitoring, regulatory compliance, and informed decision-making throughout the product lifecycle.

What Is a PBRER?

The Periodic Benefit-Risk Evaluation Report (PBRER) is the internationally harmonised reporting format introduced under ICH E2C(R2). It was developed to standardise periodic reporting across multiple regulatory jurisdictions while shifting the focus beyond safety summaries toward an integrated benefit-risk assessment. PBRER replaced PSUR in 2012 to emphasize benefit-risk evaluation.

Unlike earlier safety-focused reports, a PBRER evaluates both benefits and risks using interval and cumulative safety data, estimated cumulative exposure, interval patient exposure, and all available clinical evidence. The report includes a structured benefit-risk analysis, enabling regulatory authorities to determine whether the medicine continues to demonstrate a favourable benefit-risk balance. As a result, the PBRER plays an essential role throughout clinical development and post-authorisation surveillance by supporting continuous evaluation of patient health and public health.

PBRER vs PSUR: Key Differences at a Glance

Comparison of PBRER and PSUR

Criteria	PSUR	PBRER
Full name	Periodic Safety Update Report	Periodic Benefit-Risk Evaluation Report
Regulatory basis	EU pharmacovigilance legislation, GVP Module VII	ICH E2C(R2) guideline
Primary focus	Periodic evaluation of product safety with integrated benefit-risk assessment in modern EU practice	Comprehensive benefit-risk evaluation using a harmonized international format
Benefit information	Included in modern reports	Central component of the report
Data scope	Post-marketing safety data, exposure information, literature, signal evaluation, regulatory actions	Safety and efficacy information, cumulative and interval analyses, benefit-risk evaluation
Terminology	Official legal term in the European Union and several other regions	International ICH terminology adopted by many global regulators
Submission	Submitted according to regional regulatory requirements and reporting interval	May serve as the global core report where accepted by local regulatory authorities

Although the names differ, both documents rely on similar scientific principles. They analyze safety databases, line listings, clinical trial summaries, literature findings, and other relevant evidence to evaluate whether new rare adverse reactions, important risks, or significant findings require regulatory action.

The Main Practical Difference

Historically, the PSUR was designed primarily to summarise newly collected safety information during a defined reporting interval. The introduction of the PBRER in pharmacovigilance fundamentally changed this concept by placing periodic benefit-risk evaluation at the centre of the report rather than simply presenting accumulated adverse event data.

Today, however, the distinction is much smaller than many professionals assume. In the European Union, the legally required document is still called a PSUR, but its content closely follows the PBRER structure described in ICH E2C(R2). Consequently, the practical difference often lies in regulatory terminology rather than in two fundamentally different scientific documents. Both formats ultimately support protecting patient health by providing an explicit overall evaluation of a medicinal product’s benefit-risk profile.

Are PBRER and PSUR the Same Document?

The short answer is no, but in many cases, they are very similar.

Historically, the Periodic Safety Update Report (PSUR) and the Periodic Benefit-Risk Evaluation Report (PBRER) were not identical. Traditional PSURs primarily summarised post-marketing safety experience, whereas the PBRER, introduced through ICH E2C(R2), established a harmonised international format centred on an integrated benefit-risk assessment.

Today, the distinction is less pronounced. In the European Union, the legally required document is still called a PSUR, but its structure and scientific content largely follow the PBRER framework. Nevertheless, the terms should not be used interchangeably without considering the requirements of the relevant regulatory authorities. Some jurisdictions explicitly require a PSUR, while others accept or request a PBRER or a different periodic reporting format. Always verify local regulatory expectations before preparing or submitting a report.

PBRER and PSUR Content and Structure

Both PBRERs and modern PSURs are designed to provide a structured scientific evaluation of a medicinal product throughout its lifecycle. Rather than presenting isolated safety information, these reports integrate evidence from multiple sources to support regulatory decision-making and continuous pharmacovigilance activities.

The content typically combines information from individual adverse event reports, safety databases, aggregate data, published literature, ongoing signal management activities, regulatory actions, and exposure analyses. Depending on the product’s development stage, reports may also reference clinical trials, ongoing clinical trials, clinical trial summaries, and relevant post-authorisation studies.

An effective report goes beyond describing data. It provides a scientific analysis of whether new evidence changes the medicinal product’s safety profile, affects its benefit-risk profile, or requires updates to the company’s core data sheet, reference safety information, product labelling, or the risk management plan. This integrated approach enables marketing authorisation holders and regulatory authorities to make informed decisions while maintaining global pharmacovigilance compliance.

Main Sections of a PBRER

Although individual regulatory expectations may vary, the ICH E2C(R2) guideline defines a harmonised structure for the PBRER. A typical report includes:

• Introduction and reporting scope
• Worldwide marketing authorisation status
• Actions taken for safety reasons
• Changes to reference safety information
• Estimated exposure during the reporting interval and estimated cumulative exposure
• Presentation of individual adverse event reports and aggregate data
• Signal evaluation and safety findings
• Evaluation of risks, including rare adverse reactions
• Benefit evaluation using available clinical evidence
• Integrated benefit-risk analysis
• Conclusions regarding the overall benefit-risk balance

Rather than functioning as a collection of case summaries, the document provides an evidence-based assessment of whether the available information continues to support a favourable benefit-risk profile.

Structure of a Modern PSUR

Modern European PSURs closely follow the principles established by ICH E2C(R2). Although the document retains its legal name within the European Union, its structure includes a comprehensive benefit-risk assessment supported by a critical interpretation of all available evidence.

The report should explain not only what new safety data have emerged but also why those findings are clinically relevant. This includes evaluating signals, changes in patient exposure, effectiveness information when applicable, and the potential impact on regulatory decisions. Depending on national and regional requirements, additional regional appendices or supporting documentation may also be necessary.

Regulatory Requirements for PBRER and PSUR by Region

Because pharmacovigilance legislation varies across jurisdictions, companies cannot assume that a single reporting format automatically satisfies every regulator. While the scientific principles are increasingly harmonised, submission requirements, terminology, and reporting procedures remain region-specific.

European Union Requirements

Within the European Union, the official regulatory term remains Periodic Safety Update Report (PSUR). Requirements are defined in GVP Module VII, which aligns the report structure with ICH E2C(R2) while maintaining EU-specific legal obligations.

Submission schedules are generally determined by the European Union Reference Dates (EURD) list or by the conditions of the marketing authorisation. Many products undergo the PSUR Single Assessment (PSUSA) process, allowing multiple marketing authorisation holders to submit reports for the same active substance within a coordinated assessment procedure.

Each report is prepared using an applicable Data Lock Point (DLP), ensuring that all relevant safety data collected before the cutoff date is included. Maintaining the correct DLP is essential for complete scientific evaluation and regulatory compliance.

United Kingdom Requirements

Following Brexit, the MHRA continues to require PSURs for many medicinal products, although submission requirements may differ from those applied within the European Union.

Marketing authorisation holders should always verify the specific conditions attached to each authorisation, including reporting frequency, submission procedures, and whether any UK-specific requirements apply. Depending on the authorisation pathway, reporting schedules may differ from EU timelines.

United States Requirements

The United States generally does not require PSURs as its standard post-marketing reporting format. Instead, the FDA requires products to comply with local periodic reporting requirements, including PADER (Periodic Adverse Drug Experience Reports) and PAER for biological products.

Some companies prepare a global PBRER for internal safety evaluation while simultaneously producing FDA-specific reports. However, a global PBRER cannot automatically replace locally required periodic reports unless specifically accepted under applicable FDA procedures.

Other Global Markets

Many ICH member countries accept the PBRER format as the basis for periodic safety reporting. Nevertheless, reporting frequency, submission procedures, local appendices, and country-specific regulatory expectations continue to vary and should always be confirmed before submission.

Reporting Frequency, Data Lock Point and Submission Timelines

Preparing a PSUR or PBRER requires more than collecting safety data. Marketing authorisation holders must determine the correct reporting cycle, establish the applicable Data Lock Point (DLP), and ensure that each report complies with regional submission requirements. These elements define the reporting interval, influence the scope of the scientific analysis, and help ensure consistent regulatory compliance across multiple markets.

International Birth Date and Data Lock Point

The International Birth Date (IBD) – sometimes referred to as the Development International Birth Date (DIBD) during clinical development – serves as the global reference date from which reporting cycles are established. After a medicinal product is authorised, the IBD is used to determine the appropriate reporting interval for periodic reports in many jurisdictions.

The Data Lock Point (DLP) is the cutoff date for data included in a PSUR or PBRER. All safety data, exposure information, literature findings, and completed signal evaluations available up to the applicable Data Lock Point must be incorporated into the report. Selecting the correct DLP is essential because it defines the evidence included in the scientific analysis and supports a complete and reliable evaluation of the product’s safety profile.

Reporting and Submission Frequency

There is no universal schedule for periodic reporting. The required reporting frequency depends on several factors, including the product’s lifecycle, applicable legislation, approval conditions, and decisions made by regulatory authorities.

Global companies often prepare one core report for the global reporting cycle while adapting submission timelines to local requirements. In the European Union, reporting schedules are generally based on the European Union Reference Dates (EURD) list, whereas other markets may establish different submission dates or request additional documentation. PBRER submissions can occur on 1 to 16 yearly cycles. Some authorities may also require annual safety reports, annual reports, or, in specific regulatory contexts, quarterly reports for certain products or development programs. Because submission obligations vary, companies should always verify national and regional requirements rather than assuming a fixed reporting schedule.

How to Determine Whether a PSUR or PBRER Is Required

Determining whether a PSUR or PBRER is required starts with reviewing the regulatory obligations for each market where the medicinal product holds a marketing authorisation. While many companies prepare a global PBRER, local regulatory authorities may require a PSUR or another periodic reporting format.

A practical approach is to:

• Identify all authorised countries;
• Verify the terminology and required report format;
• determine whether a global PBRER is accepted;
• confirm the International Birth Date (IBD), applicable Data Lock Point, and reporting interval;
• review local submission schedules, including any requirements under a purely national assessment procedure where applicable;
• Align pharmacovigilance and regulatory affairs teams on responsibilities and timelines.

A well-defined reporting strategy supports global pharmacovigilance compliance, minimises submission risks, and helps ensure consistent regulatory compliance across all markets.

Common Challenges and Best Practices

Preparing high-quality periodic safety reports requires close collaboration across pharmacovigilance, regulatory affairs, medical writing, epidemiology, clinical, and data management teams. Even organisations with mature pharmacovigilance systems frequently encounter operational and scientific challenges.

Common Challenges in PBRER and PSUR Preparation

Several recurring issues can affect report quality and delay submissions:

• Inconsistent safety data across multiple safety databases.
• Incorrect estimated cumulative exposure or interval exposure calculations.
• Delayed signal detection or incomplete evaluation of newly identified safety concerns.
• Weak linkage between identified risks, supporting evidence, and conclusions.
• Inconsistencies between the report, the risk management plan, the reference safety information, or the company’s core data sheet.
• Incorrect selection of the applicable Data Lock Point.
• Reports that summarise information without providing the comprehensive and critical analysis expected by regulators.
• Different local submission schedules create coordination challenges across global markets.

Best Practices for Report Preparation

Organisations can improve report quality and submission efficiency by implementing structured planning processes well before the Data Lock Point.

Recommended practices include:

• Begin report planning several weeks before the DLP.
• Assign clear ownership for each data source and report section.
• Perform reconciliation between adverse event reporting systems, literature review activities, and exposure datasets.
• Maintain a detailed authoring calendar with predefined review milestones.
• Ensure that signal evaluation, benefit assessment, and risk evaluation remain scientifically consistent throughout the report.
• Conduct independent medical, regulatory, and quality reviews before finalisation.
• Verify compliance with all applicable local requirements immediately before submission.

Where possible, use integrated digital platforms or a validated web client to streamline collaboration, version control, and document review across global teams.

Conclusion: Understanding PBRER vs PSUR

Understanding the difference between PSUR and PBRER is essential for effective pharmacovigilance and regulatory compliance. While the two reports originated with different objectives, modern PSURs – particularly in the European Union – closely follow the harmonised PBRER framework established by ICH E2C(R2). Selecting the correct report depends on regional regulatory requirements, reporting timelines, and submission procedures rather than terminology alone. By maintaining high-quality periodic safety reporting, organisations can support informed benefit-risk assessment, strengthen drug safety monitoring, and ultimately help protect patient and public health worldwide.

FAQ

Is a PBRER a Replacement for a PSUR?

Not necessarily. The PBRER is the harmonised reporting format introduced by ICH E2C(R2), while PSUR remains the legal term in the European Union and several other jurisdictions. Whether one can replace the other depends on the requirements of the relevant regulatory authority.

Can One PBRER Be Submitted in Multiple Countries?

In many cases, yes. A global PBRER can support submissions in multiple ICH markets. However, some countries require local adaptations, additional appendices, or country-specific periodic reports, so local regulatory requirements should always be verified before submission.

Does a PBRER Include Efficacy Data?

Yes. Unlike traditional safety-focused reports, a PBRER includes relevant efficacy or effectiveness information when it may influence the overall benefit-risk balance. This integrated evaluation is a key feature of the ICH E2C(R2) format.

What Is the Difference Between PBRER and DSUR?

A PBRER is prepared for authorised medicinal products during the post-marketing phase, whereas a Development Safety Update Report (DSUR) is used during clinical development and ongoing clinical trials. DSURs are submitted annually within 60 days after the data lock point. DSURs evaluate the evolving safety profile of investigational products, while PBRERs assess the benefit-risk profile of marketed medicines.